Amendments to Thailand’s Drug Act

May 21, 2019

Amendments to Thailand’s Drug Act

On April 16, 2019, the Drug Act (No. 6) B.E. 2562 was published in the Government Gazette, amending the previous drug registration processes, clinical research processes, and fee schedules. The changes will apply to all pending applications and those filed from October 13, 2019 onward.

New Requirements for Registration

An additional requirement has been added to the registration process for new drugs. Along with the drug registration dossier, the following documents must now be submitted for each drug classification:

For modern drugs—documents that show the publication numbers of published patent or petty patent applications.
For traditional drugs—documents that show the registration of right concerning Thai traditional medicine in accordance with the Protection and Promotion of Traditional Thai Medicine Knowledge Act B.E. 2542 (1999).

Validity of Certificates of Registration

Whereas drug formula registration certificates did not expire under the previous law, under the amended Act they must be renewed every seven years. After a certificate expires, the holder has a one-month grace period to file a renewal application, provided the late application is deemed “reasonable,” and subject to a fine of one-half the rate of the respective type of license plus THB 500 for each day past the certificate’s expiry.

The Thai Food and Drug Administration (FDA) has defined the validity of existing drug formula registration certificates as follows:
certificates issued prior to September 11, 2019, as follows:
certificates registered before January 1, 1997, will expire October 13, 2024;
certificates registered from January 1, 1997, to December 31, 2007, will expire October 13, 2026; and,
certificates registered from January 1, 2008, up to October 13, 2019, will expire October 13, 2028.

Optimized Drug Registration Administration

Also incorporated into the Act is Order No.77/2559 of the Head of the National Council for Peace and Order, concerning the efficiency of registering health products. The main provisions of that order are as follows:

The FDA’s product approval timeline must not exceed the time specified in its public manuals.
The FDA will consider the official fee schedule (as announced by the Minister of Public Health from time to time) in its approval process. Further, unlike in the past, official fees earned by the FDA will not be refunded to the Ministry of Finance as government revenue, but will instead be used to improve the approval procedure.
The FDA will outsource some work, such as onsite inspections and evaluations of technical documents, to external experts of local or overseas agencies, who have been approved by, and registered with, the FDA.

Guidelines for Clinical Research Compliance

A new section was added on the procedure, regulations, and conditions of drug research and the penalties for noncompliance.

The Minster of Public Health now has the power to set and change procedures, regulations, and conditions for drug research by announcing them in the Government Gazette.
The secretary-general of the FDA can temporarily suspend, completely stop, or order an improvement of a drug research study not complying with the minister’s published guidelines.
Violating an order of the secretary-general of the FDA is subject to a fine of up to THB 100,000.

For more information on the notification, or on any aspect of the pharmaceutical industry in Thailand, please contact our Bangkok office at [email protected] or +66 2056 5555.

Related Professionals

Atthachai Homhuan

Director, Regulatory Affairs

Thailand

+66 2056 5610

Email

RELATED INSIGHTS

September 7, 2023

Thailand Health Claims for Food Supplements and Tips for the Industry

Thailand is a member state of the ASEAN Economic Community, and next year, it is expected that the ASEAN Harmonization of Traditional Medicines and Health Supplements will be signed by the economic minister of each ASEAN country. Following ratification, the ASEAN Guidelines on Claims and Claims Substantiation for Traditional Medicines and Health Supplements will become the standard guidelines in the region, and various implementation efforts and instruments will follow. These guidelines cover a wide range of medicines and supplements; however, it is not possible to cover all herbal products. There are three types of health supplement claims: nutritional claims, functional claims, and disease risk reduction claims. Examples of the three types of claims include the following: Nutritional claims: supplements nutrition, nourishes the body, supports healthy growth and development, etc. Functional claims: maintains healthy joints, supports immunity, maintains liver function, etc. Disease risk reduction claims: helps to reduce risk of dyslipidemia, helps to reduce risk of osteoporosis, etc. The degree of evidence required for substantiating disease risk reduction claims is higher than for functional claims and nutritional claims. Functional claims and disease risk reduction claims must be substantiated by efficacy studies and the relevant toxicity data. It is the responsibility of the health supplement company to provide the required evidence in order to comply with the criteria for making such claims. Tips on Health Claims for Health Supplements 1. Nutritional Claims For essential nutrients such as vitamins and minerals, as listed by the Thai Food and Drug Administration (FDA), the amount included in a supplement must be between 15% and 100% of the Thai Recommended Daily Intake (RDI) values. Rules for specific kinds of nutritional claims are provided in the Notification of the Thai FDA RE: Nutrient Function Claims. For example, the nutrients that can be claimed as boosting the

August 29, 2023

New Developments in Thailand’s Cannabis Law

Since the June 9, 2022, delisting of all parts of the cannabis plant according to the Narcotics Code, there has been an explosion of cannabis dispensaries operating in Thailand. The Department of Thai Traditional and Alternative Medicine (DTTAM) has issued more than 12,000 cannabis dispensary licenses to businesses in Thailand. A license allows a dispensary to sell cannabis flowers legally. In addition, the DTTAM requests the cooperation of dispensaries in submitting monthly reports about the sourcing, selling, and inventory of cannabis flowers. The DTTAM may suspend the selling license of dispensaries that fail to submit these reports. Apart from the enforcement duties and administrative acts of the DTTAM, the enactment of the laws and regulations pertaining to cannabis seemed to be drastically winding down. One of the reasons was that Thailand had delays in the process of forming a new government following the general election of May 14, 2023. These delays dampened Thailand’s thriving cannabis industry. In particular, the industry has concerns about the uncertainty of the nascent cannabis law. On August 11, 2023, the Narcotics Control Division of the Thai Food and Drug Administration (FDA) posted the Draft Regulation Re: Application for Approval and Approval for Manufacture, Importation, Exportation, Distribution or Possession of Narcotics under Category 5 (Extracts from Cannabis or Hemp Plants Only). This may be the first regulation that the newly formed government implements with regard to cannabis extracts. Unlike the DTTAM’s enforcement activities, the Thai FDA requests that a domestic manufacturer, importer, exporter, or seller of cannabis extracts apply for a license. The Thai FDA, as the authority, will consider granting a license only in the following cases: For medical benefits; For commercial or industrial benefits; For the benefit of medical or scientific analysis or research; and For use by the government for preventing and

August 29, 2023

Laos Issues Medical Device Regulation

Laos’ Ministry of Health (MOH) has promulgated a regulation detailing registration and notification protocols for medical devices. Decision on the Registration and Notification of Medical Devices No. 1470/MOH will come into force 60 days after both the signing of the regulation (which already occurred in July) and publication in the Official Gazette, which has not yet been specified by the government. Registration of medical devices in Laos is mentioned in the country’s Law on Drugs and Medical Products No. 07/NA, dated December 21, 2011, but a registration procedure has not been put in place. There was only a separate requirement to furnish certain required documents when importing medical devices. Now, the decision outlines the registration and notification process for medical devices through the Ministry of Health’s Food and Drug Department (FDD), in line with the regulatory principles in the ASEAN Medical Device Directive of 2015, which Laos has ratified. Medical Devices in Laos The decision defines medical devices as any instrument, apparatus, implement, machine, appliance, implant, in vitro reagent or calibrator, software, material, or other similar or related article intended for any of the following uses in humans: Diagnosis, prevention, monitoring, recovery from, or alleviation or treatment of a disease; Diagnosis, monitoring, recovery from, or alleviation of or compensation for an injury; Replacement, modification, or support of anatomy or a physiological process; Supporting and sustaining life; Controlling or assisting in conception; or Disinfection and sterilization of tools and medical devices. Medical devices in Laos are given one of four classifications based on their level of risk: Class A – Low risk (e.g., rubber belts, cotton for medical purposes, nonwoven swabs, adhesive bandages) Class B – Low-moderate risk (e.g., neonatal suction equipment, surgical gloves, gastro-catheters) Class C – Moderate-high risk (e.g., endoscopic surgical equipment, anesthesia equipment, peritoneal dialysis equipment) Class

July 11, 2023

Indonesia’s First Draft of Omnibus Health Law Shows Promise

Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning

You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

Industries

Practices

May 21, 2019